Clinical Trials in New York

Showing 12401-12420 of 22,668 trials

COMPLETEDNA< 1 mile

Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos

NCT02103153

The purpose of this study is to evaluate the PICOSURE Laser System for the treatment of unwanted tattoos

Unwanted Tattoos

Cynosure, Inc.44 participantsStarted Sep 2013

New York, New York, United States

TERMINATEDPhase 2< 1 mile

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

NCT02749227

This is a phase II, open-label, 12-month pilot study in 10 patients with silent corticotroph pituitary tumors testing the hypotheses that Pasireotide long-acting release (LAR) treatment of patients with silent corticotroph pituitary tumors and elevated plasma Proopiomelanocortin (POMC) levels will reduce plasma POMC levels and this will be associated with a reduction in pituitary tumor size. Pasireotide LAR 40 mg will be administered monthly. Baseline and monthly visits on therapy will monitor plasma levels of POMC, other pituitary function, safety labs, glucose tolerance, physical examination, and visual fields. Pituitary magnetic resonance imaging (MRI) will be done at baseline, 6 months and 12 months of therapy. The eligible patient population will consist of adult patients with known silent corticotroph pituitary tumors and elevated plasma levels of POMC.

Pituitary TumorACTH-producing Pituitary Tumour

Columbia University4 participantsStarted Jul 2017

New York, New York, United States

COMPLETEDNA< 1 mile

Misoprostol Dose and Timing Before Surgical Abortion at 13 to 16 Weeks' Gestation: a Randomized Trial

NCT02279914

This study is a blinded randomized trial to compare two different doses and intervals of buccal misoprostol for cervical preparation before surgical abortion at 13 to 16 weeks' gestation: 400 mcg administered 3 hours before D\&E (dilation and extraction), and 600 mcg administered 1.5 hours before D\&E. Primary objective: To compare operative times after two different doses and intervals of misoprostol using a non-inferiority design. Secondary objectives: To compare the doses and intervals of misoprostol for differences in: (1) initial cervical dilation; (2) need for mechanical dilation and ease of dilation if required; (3) ability to complete the abortion procedure without further cervical preparation; (4) complications; (5) provider variables including ease of procedure and satisfaction with cervical preparation; (6) patient variables including pre-operative side effects, post-operative pain, and acceptability

Abortion, Induced

Planned Parenthood of Greater New York118 participantsStarted Nov 2014

New York, New York, United States

Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

Misoprostol Dose and Timing Before Surgical Abortion at 13 to 16 Weeks' Gestation: a Randomized Trial

Find Trials by Condition in New York

Corneal Collagen Cross-Linking for Ectasia (CXL)

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease

Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults

Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries

Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism

Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients

Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Global Anticoagulant Registry in the Field

Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)